Palpitations Associated With Nicotinamide Adenine Dinucleotide (NAD+) Injections
Palpitations reported during NAD+ administration are most commonly related to infusion-related cardiovascular effects, such as transient vasodilation with reflex tachycardia. [1][2] NAD+ administration can also trigger infusion reactions that manifest with autonomic symptoms, including chest tightness and increased heart rate. [1][2][3]
Infusion Rate–Related Reflex Tachycardia
Rapid NAD+ dosing through IV routes can cause systemic vasodilation. [2] Vasodilation can produce blood pressure decreases, which can trigger reflex tachycardia that is perceived as palpitations. [2] Reports from real-world tolerability monitoring describe cardiovascular physiologic changes during infusion along with other symptoms, which supports an acute administration-related mechanism rather than delayed toxicity. [1]
Infusion Reaction and Hypersensitivity
NAD+ administration can cause infusion-related symptom clusters that can include chest tightness and tachycardia. [2] Palpitations are listed as a possible NAD+ infusion side effect in patient-facing safety information, consistent with an acute reaction pattern during or shortly after dosing. [3] Allergic or hypersensitivity-type reactions are possible contributors when palpitations occur together with flushing, itching, hives, or shortness of breath. [3]
Volume and Formulation Effects
Intravenous NAD+ is commonly administered diluted in saline, which can contribute to transient physiologic stress during infusions, especially with higher total volume or faster infusion completion. [1] Real-world tolerability monitoring tracks resting heart rate and blood pressure during NAD+ infusions, indicating that hemodynamic changes occur in at least some recipients during administration. [1]
Co-medications and Substances That Can Worsen Tachycardia
Concomitant stimulants or cardiovascular-interacting agents can increase susceptibility to perceiving tachycardia as palpitations during NAD+ administration when reflex heart rate increases occur. [2] Electrolyte abnormalities and underlying arrhythmia predisposition can also increase symptomatic sensitivity to any transient heart-rate acceleration during infusion-related hypotension or vasodilation. [2]
When Evaluation Is Urgent
Palpitations occurring with chest pain, syncope, shortness of breath, or persistent symptoms after infusion completion should be treated as urgent due to the need to exclude clinically significant arrhythmia or hypersensitivity reaction. [3]
Medication-Specific Safety Note (Route and Regulation)
Many NAD+ products are administered in off-label or compounding contexts, which can vary by preparation and administration protocol and may affect tolerability patterns, including infusion-related symptoms. [4]
Expected Symptom Timing Pattern
Infusion-rate effects tend to produce symptoms during infusion and/or near completion, consistent with an acute physiologic response to administration rather than a delayed adverse drug effect. [1][2]
Suggested Diagnostic Linkage (Clinical Correlation)
Palpitations that correlate with infusion start or infusion speed most strongly suggest a reflex tachycardia or infusion reaction mechanism. [1][2] Palpitations that correlate with other hypersensitivity symptoms suggest hypersensitivity as a competing mechanism. [3]